Wednesday, June 05, 2019

InflaRx Downgrade?

Huh? SVB Leerink cuts the price target of InflaRx N.V. (Ticker: IFRX) from $67 to $4 because of the poor results from the phase IIb trial for chronic inflammatory skin disorder. The stock is currently trading down ~90% at ~ $3.20 (closed at $37.29 day before). What a gutsy move to downgrade after the clinical results! Seriously!? There are very few analysts, who are good at their job. Majority just follow the herd mentality. That’s why I seldom pay any attention to the analysts calls.


Post a Comment

<< Home